By Marie Rosenthal
The first biosimilar to Humira, adalimumab-atto (Amjevita, Amgen), is now available in the United States, Amgen announced.
Adalimumab-atto, an anti-tumor necrosis factor (TNF)-alpha monoclonal antibody (mAb), was the first biosimilar to Humira (AbbVie) approved by the FDA in 2016, and is the first to come to market. About seven biosimilars of adalimumab are expected to come to market this year.